Nozaki Yuka, Ose Yuko, Ohmori Chinatsu, Mizunoe Yuhei, Kobayashi Masaki, Saitoh Akiyoshi, Higami Yoshikazu
Laboratory of Molecular Pathology and Metabolic Disease, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba 278-8510, Japan.
Laboratory of Pharmacology, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba 278-8510, Japan.
Int J Mol Sci. 2025 Apr 29;26(9):4219. doi: 10.3390/ijms26094219.
Obesity is defined as abnormal or excessive accumulation of body fat and contributes to several metabolic disorders. White adipose tissue (WAT) releases energy as free fatty acids and glycerol from triglycerides through a process called lipolysis. People with obesity have impaired catecholamine-stimulated lipolysis, but comprehensive understanding of this lipolysis is still unclear. We previously showed that expression of WW domain-containing E3 ubiquitin ligase 1 (WWP1), a member of the HECT-type E3 family of ubiquitin ligases, was increased in WAT of obese mice. In this study, we generated knockout (KO) mice to evaluate the effect of WWP1 in WAT of obese mice. The mRNA levels of beta-3 adrenergic receptor (), which were decreased with a high-fat diet, were increased by KO in WAT. Moreover, KO mice showed increased phosphorylated hormone-sensitive lipase levels in WAT. In contrast, noradrenaline and its metabolism were not altered in WAT of obese KO mice. These findings indicate that WWP1, which is increased in adipocytes because of obesity, is a candidate for suppressing lipolysis independently of noradrenaline metabolism. We anticipate that inhibition of WWP1 is a promising approach for a new treatment of obesity and type-2 diabetes using Adrb3 agonists.
肥胖被定义为体内脂肪异常或过度积累,并会引发多种代谢紊乱。白色脂肪组织(WAT)通过一种称为脂解的过程,从甘油三酯中释放出游离脂肪酸和甘油作为能量。肥胖人群的儿茶酚胺刺激的脂解功能受损,但对这种脂解作用的全面了解仍不清楚。我们之前发现,泛素连接酶HECT型E3家族成员含WW结构域的E3泛素连接酶1(WWP1)在肥胖小鼠的白色脂肪组织中表达增加。在本研究中,我们构建了基因敲除(KO)小鼠,以评估WWP1在肥胖小鼠白色脂肪组织中的作用。高脂饮食会降低β-3肾上腺素能受体()的mRNA水平,而白色脂肪组织中的基因敲除使其水平升高。此外,基因敲除小鼠白色脂肪组织中磷酸化激素敏感性脂肪酶水平升高。相比之下,肥胖基因敲除小鼠白色脂肪组织中的去甲肾上腺素及其代谢未发生改变。这些发现表明,因肥胖而在脂肪细胞中增加的WWP1是独立于去甲肾上腺素代谢抑制脂解的一个候选因素。我们预计,抑制WWP1是使用Adrb3激动剂治疗肥胖症和2型糖尿病的一种有前景的新方法。